We next tested a set of six commercially available EGFR/ERBB inhibitors consisting of four reversible (erlotinib, sapitinib, gefitinib and lapatinib) and two irreversible (afatinib and poziotinib) compounds in an extended panel of seven chordoma cell lines, including the three previously tested ones (Table 3). Here, EGFR is linked to chordoma.